Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Blood blood.2024025945.

https://doi.org/10.1182/blood.2024025945

Published: 2024

Includes: Supplemental data

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Risk Factors Beyond Chemo-Radiotherapy Exposure for Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML) Development in Breast Cancer Survivors: A 15-Year SEER-Medicare Analysis

Abhay Singh Singh, Megan M. Herr, Theresa E. Hahn, Swapna Thota

Blood (2022) 140 (Supplement 1): 934–935.

https://doi.org/10.1182/blood-2022-159973

Published: 2022

Journal Articles

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Frederick L. Locke, Caron Jacobson, Long Ma, Hua Dong, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Abu-Sayeef Mirza, Sarah Nikiforow, Hairong Xu, Marcelo C Pasquini

Blood (2021) 138 (Supplement 1): 530.

https://doi.org/10.1182/blood-2021-149679

Published: 2021

Journal Articles

Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients

Megan M. Herr, Paul K. Wallace, Yali Zhang, George L. Chen, Sophia R. Balderman, Maureen Ross, Christine Ho, Jens Hillengass, Eunice S. Wang, Amanda Przespolewski, Elizabeth A. Griffiths, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Paola Ghione, Philip L. McCarthy, Theresa E. Hahn

Blood (2021) 138 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2021-150954

Published: 2021

Journal Articles

DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors

Abhay Singh Singh, Nuria Mencia-Trinchant, Elizabeth A. Griffiths, Mahesh Swaminathan, Matthew Gravina, Rutaba Tajammal, Mark G. Faber, Marc S. Ernstoff, LunBiao Yan, Eti Sinha, Megan M. Herr, Duane C Hassane, Monica L. Guzman, Amanda Przespolewski, Eunice S. Wang, Swapna Thota

Blood (2021) 138 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2021-150347

Published: 2021

Journal Articles

Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-142622

Published: 2020

Journal Articles

Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy

Abhay Singh, MBBS,MPH, Nuria Mencia-Trinchant, PhD, Elizabeth A. Griffiths, MD, Matthew Gravina, MD, Rutaba Tajammal, MD, Mark G. Faber, DO, Annmarie Nowak, Marc S. Ernstoff, MD, LunBiao Yan, PhD, Megan M. Herr, PhD, Duane C. Hassane, PhD, Monica L. Guzman, PhD, Eunice S. Wang, MD, Amanda Przespolewski, DO, Swapna Thota, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-141617

Published: 2020

Journal Articles

β2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogenic Transplantation While Preserving Graft Versus Leukemia Effect

Hemn Mohammadpour, PhD DVM, Joseph L. Sarow, BS, George L. Chen, MD, Cameron R. MacDonald, BS, Umesh Sharma, MD, Megan M. Herr, PhD, Theresa E. Hahn, PhD, Elizabeth A. Repasky, PhD, Philip L. McCarthy, MD

Blood (2019) 134 (Supplement_1): 1915.

https://doi.org/10.1182/blood-2019-123139

Published: 2019

Journal Articles

Risk for New Malignancies of Potential Infectious Etiology Among Adult Survivors of Specific Non-Hodgkin Lymphoma Subtypes

Megan M Herr, PhD, Sara J. Schonfeld, PhD, Graca M. Dores, MD MPH, Margaret A. Tucker, MD, Rochelle E Curtis, MA, Lindsay M Morton, PhD

Blood (2016) 128 (22): 2414.

https://doi.org/10.1182/blood.V128.22.2414.2414

Published: 2016

Journal Articles

Patterns of Cutaneous Malignancy Risk Among Survivors of Non-Hodgkin Lymphoma Subtypes

Lindsay M Morton, PhD, Megan M Herr, PhD, Sara J. Schonfeld, PhD, Graca M Dores, MD MPH, Rochelle E Curtis, MA, Margaret A. Tucker, MD

Blood (2016) 128 (22): 4771.

https://doi.org/10.1182/blood.V128.22.4771.4771

Published: 2016

Journal Articles

Clinical Features, Treatment, and Survival of Secondary Central Nervous System Lymphoma

Megan M. Herr, BS, Paul M. Barr, MD, David Q Rich, ScD, Nimish Mohile, MD

Blood (2014) 124 (21): 5389.

https://doi.org/10.1182/blood.V124.21.5389.5389

Published: 2014

Journal Articles

Late Relapses Following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era

Carla Casulo, MD, Hunter D Bradley, MD MPH, Megan M. Herr, BS, Ferdous Barlaskar, MD PhD, Andrew Evans, MDPhD, Richard Burack, MDPhD, Jane L. Liesveld, MD, Michael W. Becker, MD, Laurie A. Milner, MD, Paul M. Barr, MD, Jonathan W. Friedberg, MD MMSc

Blood (2014) 124 (21): 3999.

https://doi.org/10.1182/blood.V124.21.3999.3999

Published: 2014

Journal Articles

Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas

Beata Holkova, MD, Maciej Kmieciak, PhD, Prithviraj Bose, MD, Paul M. Barr, MD, Mary Beth Tombes, RN, Ellen Shrader, BS, Erin Cebula, MPH, CCRP, Emily Pierce, RN, CCRC, Megan M. Herr, BS, Heidi Sankala, PhD, Changyong Feng, PhD, Richard I Fisher, MD, Steven Grant, MD, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 4375.

https://doi.org/10.1182/blood.V122.21.4375.4375

Published: 2013

Journal Articles

Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study

Paul M. Barr, MD, Margaret M. Briehl, PhD, Steven H Bernstein, MD, Jonathan W. Friedberg, MD, Andrea Baran, MS, Derick R. Peterson, PhD, Daniel Oscar Persky, MD, Carla Casulo, MD, Megan M. Herr, BS, Jamie Littleton, BSN, Erin Cebula, MPH, CCRP, Mark Schwartz, PhD, Soham D. Puvvada, MD, Robert T Dorr, PhD, Richard I Fisher, MD, Thomas P. Miller, MD

Blood (2013) 122 (21): 89.

https://doi.org/10.1182/blood.V122.21.89.89

Published: 2013

NARROW

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Risk Factors Beyond Chemo-Radiotherapy Exposure for Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML) Development in Breast Cancer Survivors: A 15-Year SEER-Medicare Analysis

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients

DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors

Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma

Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy

β2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogenic Transplantation While Preserving Graft Versus Leukemia Effect

Risk for New Malignancies of Potential Infectious Etiology Among Adult Survivors of Specific Non-Hodgkin Lymphoma Subtypes

Patterns of Cutaneous Malignancy Risk Among Survivors of Non-Hodgkin Lymphoma Subtypes

Clinical Features, Treatment, and Survival of Secondary Central Nervous System Lymphoma

Late Relapses Following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era

Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas

Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only